




































Strategic Alliances, Joint Ventures and Licensing

2013: Market leaders in life sciences, technology, energy and cleantech, communications, financial services and many other industries turn to WilmerHale for legal advice and business advantage. Our corporate, licensing, intellectual property and regulatory lawyers have recently handled numerous strategic alliance, joint venture, licensing, collaboration, product development, outsourcing, manufacturing, distribution and similar agreements, including many significant deals that are helping to shape the future of science and technology. We have advised clients throughout the United States and Europe on strategic alliances that have received industry recognition for their importance, and our lawyers have been recognized as global leaders in this field. The following is a selection of our recent transactions.

Counsel of Choice for Strategic Alliances, Joint Ventures and Licensing

SERVING INDUSTRY LEADERS IN LIFE SCIENCES, TECHNOLOGY, ENERGY AND CLEANTECH, COMMUNICATIONS, FINANCIAL SERVICES AND BEYOND



 <p>Sale of ad network business to MediaMath</p>	 <p>Various licensing transactions</p>	 <p>Application development outsourcing deal with EPAM and renegotiation of IT outsourcing transaction with Syntel</p>	 <p>Licensing agreements and IP advice</p>	 <p>Collaboration with Jazz Pharmaceuticals to develop deuterated sodium oxybate products for narcolepsy</p>	 <p>Ophthalmic collaboration with Portola Pharmaceuticals</p>	 <p>International distribution agreements</p>	 <p>Various licensing transactions</p>	 <p>Licensing advice</p>
 <p>Collaboration, customer license and settlement transactions</p>	 <p>Drug development and commercialization agreements</p>	 <p>Licensing and manufacturing agreements</p>	 <p>Antibody discovery collaboration with Pfizer</p>	 <p>Collaboration with Menarini Group for antibody-based cancer drugs</p>	 <p>Collaboration with Roche on therapeutics for autism</p>	 <p>Collaboration with Boehringer Ingelheim to develop digital diabetes self-management programs</p>	 <p>Dispositions of software businesses</p>	 <p>Acquisitions and licensing transactions</p>
 <p>Drug development and commercialization collaborations</p>	 <p>Acquisitions and commercialization agreements</p>	 <p>Collaboration with Genzyme on RNAi therapeutics for transthyretin-mediated amyloidosis in Asia</p>	 <p>Acquisitions and licensing agreements</p>	 <p>Restructuring of collaborations with Intellikine/Millennium and Purdue/Mundipharma</p>	 <p>Video game development agreements</p>	 <p>Collaboration with Mersana Therapeutics on antibody-drug conjugates</p>	 <p>Worldwide data licensing and alliance agreements</p>	 <p>Publishing and collaboration agreements</p>
 <p>Distribution agreement with BTG for 5-FU chemotherapy overdose antidote in Europe</p>	 <p>Collaboration and option agreements with Genzyme and funding collaboration with The Leukemia & Lymphoma Society® for BET inhibitor</p>	 <p>Restructuring of collaboration with Novartis, including reversion of development-stage rights to Idenix</p>	 <p>Collaborations with Celgene, GSK, Eisai and Roche Molecular Systems</p>	 <p>Settlement and licensing agreements to resolve ANDA litigation</p>	 <p>Worldwide distribution agreements for healthcare IT products</p>	 <p>Collaboration, development and licensing transactions</p>	 <p>Drug development and licensing agreements</p>	 <p>Yandex.Money joint venture with Sberbank</p>



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

13_0332 RPI 4/13 2500

WilmerHale recognizes its corporate responsibility to environmental stewardship.

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2013 Wilmer Cutler Pickering Hale and Dorr LLP